Press Releases

Perrigo Company (Nasdaq: PRGO; TASE: PRGO) announced that it has filed with the U.S. Food and Drug Administration (FDA) an Abbreviated New Drug...

Perrigo Company (Nasdaq: PRGO; TASE) today announced that it will release financial results for its first quarter fiscal 2012 on Thursday, October 27,...

Perrigo Company (Nasdaq: PRGO;TASE) announced that it received tentative approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated...

Perrigo Company (Nasdaq: PRGO;TASE) today announced that Perrigo CFO Judy Brown and Senior Management will meet with analysts on Wednesday, October 5,...

Perrigo Company (Nasdaq: PRGO; TASE) today announced that Perrigo Chairman and CEO Joseph C. Papa and Senior Management will meet with analysts on...

Perrigo Company (Nasdaq: PRGO; TASE) today announced that it has received final approval from the U.S. Food and Drug Administration for its...

Perrigo Company (Nasdaq: PRGO; TASE) today announced it expects to issue $350 million of notes in its fiscal second quarter pursuant to its existing...

Perrigo Company (Nasdaq: PRGO; TASE) today announced results for its fourth quarter and full year ended June 25, 2011. Perrigo's Chairman and CEO...

Perrigo Company (Nasdaq: PRGO; TASE) today announced that its Board of Directors declared a quarterly dividend of $0.07 per share, payable on...

Perrigo Company (Nasdaq: PRGO;TASE) today announced that it will release financial results for its fourth quarter fiscal 2011 on Tuesday, August 16 ,...

Perrigo Company (Nasdaq: PRGO;TASE) today announced that it has closed the acquisition of Paddock...

The Perrigo Company (Nasdaq: PRGO;TASE) today announced that it has received approval from the U.S. Food and Drug Administration (FDA) to market...

Perrigo Company (Nasdaq: PRGO;TASE) today announced that it continues to work to finalize the regulatory approvals necessary to complete the...

Perrigo Company (Nasdaq: PRGO; TASE) today announced that its partner Teva Pharmaceutical Industries Ltd. (Nasdaq: TEVA) (previously Barr Laboratories...

Perrigo Company (Nasdaq: PRGO;TASE) today announced that Perrigo Chairman and CEO Joseph C. Papa will present at the Goldman Sachs 32nd Annual Global...

Perrigo Company (Nasdaq: PRGO; TASE) and its partner Synthon Pharmaceuticals, Inc. today announced that it has received tentative approval from the...

Perrigo Company (Nasdaq: PRGO; TASE) today announced that it has received final approval from the U.S. Food and Drug Administration for its abbreviated...

Perrigo Company (Nasdaq: PRGO; TASE) today announced that it has agreed to settle all Hatch-Waxman litigation relating to fluticasone lotion brought by...

Perrigo Company (Nasdaq: PRGO; TASE) today announced results for its third quarter ended March 26, 2011. Perrigo's Chairman and CEO Joseph C. Papa...

Perrigo Company (Nasdaq: PRGO; TASE) today announced that it has received final approval from the U.S. Food and Drug Administration for its abbreviated...

Perrigo Company (Nasdaq: PRGO;TASE) today announced that its Board of Directors declared a quarterly dividend of $0.07 per share, payable on June 14,...

Perrigo Company (Nasdaq: PRGO; TASE) today announced that the United States Court of Appeals for the fourth Circuit has affirmed an earlier decision...

Perrigo Company (Nasdaq: PRGO; TASE) today announced that it will release financial results for its third quarter fiscal 2011 on Tuesday, May 3, 2011...

Perrigo (Nasdaq: PRGO;TASE) today announced that its partner, Teva Pharmaceutical Industries, Ltd. (Nasdaq: TEVA), has received final OTC approval to...

Perrigo (Nasdaq: PRGO; TASE) today announced that the Detroit Office of the Food and Drug Administration (FDA) has concluded its re-inspection of...

Perrigo Company (Nasdaq: PRGO;TASE) today announced that Perrigo Chairman and CEO Joseph C. Papa will present at the Barclays Capital 2011 Global...

Perrigo (Nasdaq: PRGO;TASE) today announced that, as part of the anticipated follow-up to the warning letter Perrigo received on April 30, 2010, the...

Perrigo Company (Nasdaq: PRGO; TASE) today announced that Perrigo Chairman and CEO Joseph C. Papa will present at the Citi 2011 Global Health Care...

Perrigo Company (Nasdaq: PRGO; TASE) today announced that it has filed an Abbreviated New Drug Application for calcipotriene 0.005% and betamethasone...

Perrigo (Nasdaq: PRGO; TASE) today announced that it has begun selling OTC infant formula to Costco in Canada. The product will be sold under Costco's...

Perrigo (Nasdaq: PRGO; TASE) today announced that it has entered into an exclusive agreement with AgaMatrix, Inc. to sell and distribute blood glucose...

Perrigo Company (Nasdaq: PRGO; TASE) today announced that it has agreed to settle its Hatch-Waxman litigation relating to Minoxidil foam brought by...

-- Fiscal second quarter revenue from continuing operations increased $135 million, or 23%, to $718 million -- Fiscal second quarter GAAP income from...

Perrigo Company (Nasdaq: PRGO; TASE) today announced that its Board of Directors declared a quarterly dividend of $0.07 per share, payable on March...

Perrigo Company (Nasdaq: PRGO; TASE) today announced that it has signed a definitive agreement to acquire substantially all of the assets of Paddock...

Perrigo Company (Nasdaq: PRGO;TASE) today announced that it will release financial results for its second quarter fiscal 2011 on Tuesday, February 1,...

Perrigo Company (Nasdaq: PRGO; TASE) today announced that Perrigo Chairman and CEO Joseph C. Papa will present at the 29th Annual J.P. Morgan...

IR Global Rankings ("IRGR"), the most comprehensive technical ranking system for investor relations websites, corporate governance practices and...

JOHANNESBURG, SOUTH AFRICA -- (Marketwire) -- 12/10/10 -- www.stockcall.com/ offers investors comprehensive research on the drug related products industry and has completed analytical research on...

In the news release, Perrigo Announces Launch of Naproxen Sodium Soft Gels - Generic Equivalent to Aleve® Liquid Gels, issued 29-Nov-2010 by Perrigo over PR Newswire, we are advised by the...

Perrigo (Nasdaq: PRGO;TASE) today announced that its licensor and supplier Synthon has received final approval from the U.S. Food and Drug...

Perrigo (Nasdaq: PRGO; TASE) today announced that it has launched Naproxen Sodium Soft Gels. The product is the generic equivalent of Bayer...

IR Global Rankings (IRGR) is pleased to announce that it will collaborate with Institutional Investor magazine on a series of Investor Relations events...

Perrigo Company (Nasdaq: PRGO; TASE) today announced that Perrigo Chairman and CEO Joseph C. Papa will present at the Credit Suisse Annual...

JOHANNESBURG, SOUTH AFRICA -- (Marketwire) -- 11/09/10 -- www.wallstreetequityresearch.com brings investors market knowledge on the aspects moving the drug related products stocks, and offers...

Fiscal first quarter revenue from continuing operations increased $113 million, or 21 percent, to a record $641 million Fiscal first quarter...

Perrigo Company (Nasdaq: PRGO; TASE) today announced that its Board of Directors declared a quarterly dividend of $0.07 per share, payable on...

Perrigo Company (Nasdaq: PRGO; TASE) today announced that it will release financial results for its first quarter fiscal 2011 on Tuesday, November...

Perrigo Company (Nasdaq: PRGO; TASE) announced that it has filed with the U.S. Food and Drug Administration (FDA) an Abbreviated New Drug...

Perrigo Company (NASDAQ: PRGO)(TASE: PRGO) announced it received FDA approval from the U.S. Food and Drug Administration to manufacture and market Imiquimod Cream, 5%. Perrigo will vertically...